CytRx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that David Haen, the Company’s Vice President of Business Development, will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12, 2011, at 4:55 p.m. Eastern time (1:55 p.m. Pacific time). The conference is being held at the Waldorf=Astoria hotel in New York City.

“This well-attended conference is ideal for showcasing the rapid clinical advancement of our promising oncology portfolio,” said Steven A. Kriegsman, CytRx’s President and Chief Executive Officer. “We currently have seven clinical trials either underway or planned, with bafetinib and tamibarotene in multiple Phase 2 trials and plans to begin a Phase 2b trial with our doxorubicin conjugate INNO-206 by year end. We are now on the cusp of reaching several critical inflection points that make this a very exciting time at CytRx.”

A live webcast of the presentation will be available at: http://www.wsw.com/webcast/rrshq20/cytr.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx plans to initiate a Phase 2b clinical trial as a treatment for soft tissue sarcomas in 2011, following its Phase 1b dose escalation safety trial. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and is conducting a pharmacokinetic clinical trial in brain cancer. CytRx's pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled Phase 2 clinical trial in patients with non-small-cell lung cancer, and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). For more information on the Company, visit http://www.cytrx.com.



CONTACT:

Investor Relations:
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.